ATLANTA, March 7, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback